Relief Therapeutics – at the forefront of COVID Research

A massive race is on to find a cure for Covid-19. The most obviously delivery system being a vaccination.

Relief Therapeutics is at the forefront in this race for a drug against Covid-19. Relief Therapeutics has had some success in 2020, and their shares have jumped around 49’000% in 2020.

Positive news in October was from a trial with 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care unit (ICU) with critical COVID-19 and respiratory failure. They were treated with RLF-100™(aviptadil) and compared to 24 control patients treated in the same setting.

Overall, 81% of RLF-100™-treated patients survived beyond 60 days, compared to 17% of control patients. Patients treated with RLF-100™ demonstrated a 9-fold increased probability of survival and recovery from respiratory failure, with a high degree of statistical significance. (Statistical analysis performed by Prof. Phil Lavin, of the Boston Biostatistical Research Foundation.)

The study’s principal investigator, Dr. Jihad Georges Youssef, of the Houston Methodist Hospital stated: 'We are encouraged by these initial results in highly comorbid patients with COVID-19 respiratory failure, and we are pleased that the majority of these patients have returned safely to their families. We look forward to the upcoming results from the randomized, double-blind, prospective trial in less severely comorbid patients for confirmation of these results,'

 
Relief Therapeutics remains well in the race to make a breakthrough in the field of Covid-19 treatment. We hold thumbs for this trial and the clinical trials of all other pharmaceutical companies.